Experts Question Legality Of FDA Using CNPRV To Enter Drug-Pricing Space

By Maaisha Osman / July 25, 2025 at 2:03 PM

FDA’s new offer to accelerate approvals for companies agreeing to lower drug prices brings the agency for the first time directly into a national drug-pricing role -- a move industry lawyers suggest is on shaky legal ground given long-standing drug law restricts FDA reviewers to only assessing efficacy and safety when approving drugs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.